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Abstract: 
An innovative delivery system for melatonin, based on the incorporation of solid lipid 
microparticles in orodispersible films (ODFs) made of maltodextrin, was designed and developed. 
Lipid microparticles at two different melatonin concentrations (10 and 20% w/w) were produced 
by the spray congealing technology using two different lipid carrier (tristearin and hydrogenated 
castor oil) and characterized in terms of size, solid state, drug loading and drug release pattern. 
Tristearin microparticles were discarded due to a polymorphic modification of the carrier. The 
incorporation of hydrogenated castor oil microparticles in ODFs by using the casting method did 
not alter significantly the shape and dimension of the microparticles and the mechanical 
properties (elasticity and strength) of the films, which remained acceptable for manufacturing and 
handling. The in vitro release studies performed in saliva, gastric and intestinal simulated media on 
ODFs containing melatonin loaded in hydrogenated castor oil microaparticles revealed the 
possibility to combine with an immediate release of the drug and a sustained release over at least 
5 h period. 
In conclusion, the proposed drug delivery system maintains the advantages of ODFs, i.e. the 
suitability to be swallowed without water, and permits the tuning of drug release according to the 
clinical needs by modulating the ratio of free and microencapsulated drug in the ODF.  
 
 
 
 
Keywords:  
Melatonin; maltodextrins; spray congealing; orally disintegrating films; personalized medicine, 
modified drug release. 
 
 
 
 
  
3 
 
1. Introduction 
Melatonin, an indoleamine secreted by the pineal gland during the night, plays a key role in 
regulating circadian rhythm. The administration of this neurohormone is useful for the treatment 
of sleep disorders in both elderly1 and children.2,3,4Melatonin is available on the market as 
immediate release dosage form or modified release tablet (Circadin®). In the former case, the 
maximum plasma concentration is reached within 60 min,5 then it undergoes hepatic metabolism 
and the 80-90% is converted to 6-sulphatoxymelatonin, an inactive compound excreted in the 
urine. In Europe, the Circadin® is available on the market as a medicinal product containing 2 mg 
of melatonin in the form of prolonged release tablets and it is approved for the treatment of 
primary insomnia in patients aged 55 years and older.6The release profile from the modified 
release tablet exhibits an initially fast release (approximately a third of the dose in the first hour) 
followed by a slower prolonged release with the aim of promoting the induction and maintenance 
of sleep. Despite the relative small tablet dimensions of Circadin®, some patients (elderly, disabled 
or children) have difficulty swallowing the formulation intact and may require tablets to be divided 
or crushed to ease administration, thus producing the loss of the prolonged-release properties and 
the alteration of its clinical effect.7 Thus, new dosage forms such as solid lipid microparticles to be 
dispensed in sachets8 and hydrophilic matrix tablets based on cyclodextrins9 have been proposed.  
An alternative approach to fulfill all the requirements reported above, namely the fast onset of 
action combined with a prolonged release and easiness of swallowing, could reside in the 
development of orodispersible dosage forms that disintegrate and/or dissolve rapidly upon 
contact with saliva after being placed on the tongue and, as a consequence, permit patient to not 
swallow the intact solid dosage form, but as drug solution/suspension in saliva fluids.10 Among 
such dosage forms, orodispersible films (ODFs) appear particularly attractive since they avoid the 
fear of chocking, that still remains in the orodispersible tablets.11 Moreover, they are well 
accepted by paediatric patients and their caregivers (e.g., family members or nurse).12,13 However, 
conventional ODFs are immediate release dosage forms, thus they are not able to modulate the 
release of the loaded drug. An innovative and very interesting strategy to solve this issue, which 
could be useful for the development of a melatonin delivery systems, is the loading in the ODFs of 
a microencapsulated drug. Recently two papers published by the Breitkreutz research group at the 
Heinrich Heine University suggested that the incorporation of drug-loaded polymeric 
microparticles produced by hot-melt extrusion14 or by wet extrusion and spheronizzation15 into 
ODFs provided prolonged drug release properties. However, the selection of polymers to be used 
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in the design of microparticles is particularly critical due the possible interactions with glycerine or 
propylene glycol, which are the plasticizers most used to tune-up ODFs tensile properties. A 
possible alternative to the use of polymeric microparticle to achieve a prolonged release is 
represented by solid lipid microparticles, due to the favourable biocompatibility and lower toxicity 
of the lipids compared with many polymers 16,17 and the lack of significant interaction with 
hydrophilic plasticizers commonly used in the design of ODFs.  
The aim of this study was to investigate the feasibility of innovative ODFs as delivery system for 
melatonin able to either decrease the sleep onset latency and to increase the total sleep time, 
suitable for patients with swallowing difficulties such as children and the elderly. In the attempt to 
guarantee both a fast onset of action and a prolonged release, different ODFs formulations, 
containing melatonin-loaded lipid microparticles and/or the free dispersed drug, were studied. For 
the design of the ODF maltodextrins were selected since their use as well as the possible impact of 
formulative variables on film mechanical properties are well known. 18,19,20 
 
2. Materials and methods 
 
2.1. Materials 
Maltodextrins having a dextrose equivalent (D.E.) equal to 6 (Glucidex® IT6) were kindly obtained 
by Roquette (Lestrem, France). Glycerin (GLY), Span® 80 (S80) and Tween® 80 (T80) were 
purchased from Carlo Erba Reagenti (Milan, Italy) and Croda (Snaith, UK), respectively. Melatonin 
(MLT) was purchased from Farmalabor (Assago, Italy). MLT was milled and sieved; the fraction 
lower than 50 µm was used. Tristearin (Dynasan 118) and hydrogenated castor oil (Cutina HR) 
were a gift from Sasol (Witten, Germany) and Gattefossè Italy (Milan, Italy), respectively. All 
solvents were of analytic grade, unless specified.  
For the dissolution studies, the following media were prepared: 1) Simulated Salivary Fluid: 1 L 
contained 2.38 g Na2HPO4, 0.19 g KH2PO4 and 8 g NaCl, the pH was adjusted at 6.8 using 
phosphoric acid (H3PO4); 2) Simulated Gastric fluid: 2.92 g of NaCl and 7.04 mL of hydrochloric acid 
were dissolved in deionized water up to 1 L., finally the pH was adjusted to 1.2; 3) Simulated 
intestinal Fluid: 6.8 g of potassium dihydrogen phosphate and 0.9 g of sodium hydroxide were 
dissolved in deionized water to obtain a total volume of 1 L and the pH was adjusted to 6.8. 
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2.2 Preparation of the solid lipid microparticles  
For the microparticles (MP) production two different excipients, namely hydrogenated castor oil 
(Cutina HR, melting point 85-90°C) and tristearin (Dynasan 118, melting point 75-80 °C) were used. 
The MPs were produced by the spray congealing process using the wide pneumatic nozzle (WPN) 
already described in detail in our previous work8. Both placebo MP and MLT-loaded MP at two 
different concentrations (10 and 20 % w/w) were produced (Table 1). The excipient was melted in 
a water bath kept at 10°C above the melting point of the excipient. For the preparation of MLT 
loaded microparticles, melatonin was added to the molten excipient in two different 
concentrations and stirred for 15 minutes in order to obtain a homogeneous suspension, which 
was then loaded into the feeding chamber of the WPN. WPN parameters were set at a 
temperature of 80°C for tristearin and 95 °C for hydrogenated castor oil with an air pressure of 4 
bar.  
Microparticles were collected, sieved using a vibrating shaker (Octagon Digital, Endecotts, London, 
UK) to select the fraction between 50 and 75 m sieves (useful fraction), and stored in 
polyethylene closed bottles at 4 ± 2°C.  
 
Table 1 – microparticle composition, yield and melatonin (MLT) content  
Form.  Material Nominal MLT 
content (% w/w) 
Actual MLT 
content (% w/w) 
Useful 
yield 
MP1 tristearin 0 - - 
MP2 tristearin 10 8.6  0.1 42.3% 
MP3 tristearin 20 16.0  0.4 37.5% 
MP4 hydrogenated 
castor oil 
0 - - 
MP5 hydrogenated 
castor oil 
10 8.1  0.1 28.8% 
MP6 hydrogenated 
castor oil 
20 17.0 ± 0.1 23.8% 
 
 
 
2.3 Characterization of the solid lipid microparticles (MP) 
The useful yield was calculated from the mass of a useful fraction (50-75 m) by dividing it by the 
mass of the starting material (% w/w). 
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Differential scanning calorimetry (DSC) measurements were performed using a PerkinElmer DSC 6 
(PerkinElmer, Beaconsfield, UK) using nitrogen (20 mL/min) as purge gas. The samples, weighing 
8–12 mg, were placed into a non-hermetically aluminum pan and heated from 25 °C to 150 °C at a 
scanning rate of 10°C/min.  
 
Hot-stage microscopy (HSM) was carried out on hot stage apparatus (Mettler-Toledo S.p.A.) 
mounted on Nikon Eclipse E400 optical microscope connected to a Nikon Digital Net Camera 
DN100 for the image acquisition. The samples were heated at 25°C for 1 min for equilibration and 
then heated from 25°C to 130°C at a scanning rate of 10°C/min.  
 
The actual amount of melatonin loaded into the MP was assayed spectrophotometrically (UV-vis 
spectrophotometer mod. UV2, Unicam, Cambridge, UK) at 277 nm. Calibration solutions were 
diluted from the standard stock solution (2 mg/mL), in the concentration range of 0.5–40 µg/mL. 
The calibration curves were assessed in both standard solution pH 1.5 and 6.8. Each measurement 
was performed in triplicate and expresses as the mean ± SD was reported. The correlation 
coefficient (R2) was equal to 1 in both standard solutions. For the drug content, about 20 or 30 mg 
of MPs, according to the formulation, were accurately weighted and dispersed into 10 mL of 
opportune solution medium. The solution was heated at 10°C above the excipient melting point 
and gently shaken for 60 min. Finally, the samples were cooled to room temperature, filtered, 
appropriately diluted and assayed. Each formulation was analyzed in triplicate in both media and 
the results were expressed as the mean ± standard deviation (SD).  
 
2.4 Preparation of orodispersible films (ODFs) 
ODFs were prepared by the solvent casting technique as previously described.18 Briefly, Tween® 80 
and melatonin were directly added to the maltodextrin solution under constant stirring. In 
parallel, Span® 80 was mixed with glycerin and, then, added to the Tween® 80/melatonin mixture. 
After 30 min of mixing, microparticles were added gradually and the resulting dispersion was left 
to rest for removing bubbles. The dispersion was cast at the rate 1 m/min over a silicone release 
liner and a coating thickness of the wet mixture was set (250-350 μm) to obtain ODFs with a final 
thickness of 100-200 μm (Labcoater LTE-S(M), Mathis, CH). The dispersion was, then, dried in the 
machinery oven at 60° C for 12 min, setting the circulation speed at 1800 rpm. The obtained ODF 
was cut into the shape and size required for testing, packed in individual airtight seal packs  using a 
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triple layer film, and stored at 25±1 °C until use. The composition of the prepared films is reported 
in Table 2. 
 
Table 2 – Composition of ODFs loaded with free melatonin (MLT) and/or microparticles (MP). 
Form. 
Composition (%, w/w) Total MLT 
content 
(%, w/w) 
Maltodextrin Span80 Tween80 Glycerin MLT MP 
F1 80.30 0.78 1.55 17.37 - - - 
F2 78.29 0.76 1.51 16.94 2.50 - 2.50 
F3 75.45 0.73 1.46 16.33 6.03 - 6.03 
F4 74.80 0.72 1.45 16.18 - 6.85
1 - 
F5 56.09 0.54 1.08 12.13 - 30.16
1 - 
F6 56.09 0.54 1.08 12.13 - 30.16
2 2.50 
F7 56.09 0.54 1.08 12.13 - 30.16
3 5.69 
F8 54.67 0.53 1.06 11.83 2.50 29.41
2 5.00 
F9 52.90 0.51 1.02 11.44 5.69 28.44
3 11.38 
1 MP4: empty microparticles; 
2MP5: 8.1%, w/w melatonin actual content; 
3MP6: 17.0%, w/w melatonin 
actual content. 
 
 
2.5 Characterization of the ODFs 
The overall morphology of the ODFs were evaluated by Scanning Electron Microscopy (SEM). 
Samples were fixed on the sample holder with double-sided adhesive tape, sputter coated with 
Au/Pd under argon atmosphere performed using a vacuum evaporator (Edwards, Crawley UK) and 
examined using a ESEM Quanta 200 (Fei Company – Oxford Instruments) operating at 30.0 kV 
accelerating voltage. Three diﬀerent magniﬁcations (250X, 1000X and 5000X) were used. 
The film thickness was measured in ten different positions by using a MI 1000 (ChemInstruments, 
USA). The accuracy of the instrument was 2.5 μm± 0.5%. 
Tensile properties of ODFs loaded with free and microencapsulated drug were determined by an 
Instron 5965 texture analyzer (Instron, UK), equipped with a 10 N load cell. In order to determine 
the influence of microparticles loading on the mechanical properties of ODFs, the tests were 
performed using formulations reported in Table 2 with the high microparticle concentrations (i.e., 
F6, F8, F9). The films were cut into 8012 mm strips and were equilibrated at 25±1 °C for 1 weeks. 
8 
 
Each test strip was placed longitudinally in the tensile grips on the texture analyzer. Initial gap 
between the grips and crosshead speed were 40 mm and 12.5 mm/min, respectively. A preload 
was performed in each analysis. The test was considered concluded at the film break. The 
following parameters were determined: (i) Tensile strength (σ) was calculated by dividing the 
maximum load by the original cross-sectional area of the specimen and it was expressed in force 
per unit area (MPa). (ii) Percent elongation at break () was calculated according to Eq. (1):  
100
0
0 


L
LL
           Eq. (1) 
where L0 is the initial gage length of the specimen and L is the length at the rupture. (iii) Elastic 
modulus or Young’s modulus (Y) was calculated as the slope of the linear portion of the stress- 
curve. The result was expressed in force per unit area (MPa). (iv) Tensile energy to break (TEB) was 
defined by the area under the stress-strain curve. The results were expressed in MPa. An average 
of five measurements was taken for each type of specimen. 
The particle distribution of microparticles before and after being loaded in the film was 
determined using an AccusizerTM 780 Optical Particle size (PSS Nicomp, US). The MPs were 
suspended into a 0.01% w/v Tween® 80 aqueous solution (2 mL). The surfactant was added to 
prevent microparticle aggregation. The analyses on microparticle loaded films were performed 
dissolving a film sample (1 cm2) in 2 mL of 0.01% w/v Tween® 80 aqueous solution. Particle size 
distribution was expressed as undersize cumulative percentages of the area distribution. The 
population dispersity was referred as span, which was calculated according to the Eq. 2: 
     
       
   
          Eq. (2) 
where d90, d50, d10 are the mean diameter at the 90%, 50%, 10% of the population distribution 
respectively.  
The ODFs were also characterized by mean DSC according to the method described above. 
The melatonin content was assayed using the same protocol used for microparticles. About 20 or 
30 mg of ODFs, according to the ODF formulation, were accurately weighted and dispersed into 10 
mL of pH 6.8 buffer. The solutions were heated at 90°C and gently shaken for 60 min. Finally, the 
samples were filtered, cooled to room temperature, appropriately diluted and 
spectrophotometrically assayed. Each formulation was analyzed in triplicate and the results were 
expressed as the mean ± standard deviation (SD). 
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2.6 In vitro release studies of melatonin from microparticles and ODFs 
In vitro release studies were carried out using a USP II apparatus (Erweka DT 800 GmbH, 
Heusenstamm, Germany) with a paddle rotation at 50 rpm. The temperature was set at 37± 0.5°C. 
The dissolution test of microparticles and ODFs was performed using 500 mL of a single dissolution 
medium (simulated salivary fluid or simulated gastric fluid at pH 1.2 or simulated intestinal fluid at 
pH 6.8) for 60 minutes. 
In addition, the release tests of ODF containing free drug and/or melatonin loaded microparticles 
were carried out by changing the pH of the dissolution medium: the ODF was first dissolved in 
simulated salivary fluid (5 mL) for 5 minutes, then this dispersion was transferred into 500 mL of 
simulated gastric fluid (pH 1.2) for one hour and, finally, 250 mL of a basic solution to obtain a final 
solution at pH 6.8 to simulate the intestinal environment was added (simulated intestinal fluid). 
Overall the release experiments ran over a period of 5 h.  
Using both procedures, the medium was then the filtered through a 0.40 μm poroplast® filter and 
continuously pumped (12.5 mL/min) to a flow cell in a spectrophotometer (UV2 Spectrometer, 
Unicam, Cambridge, UK). The amount of melatonin dissolved was analysed at 277 nm. All the 
release tests were performed at least in triplicate and the mean ± SD was reported. 
The release profiles were finally compared using the similarity factor f2. The similarity factor is a 
logarithmic reciprocal square-root transformation of the sum of squared error and is a 
measurement of the closeness in percentage of dissolution between two release profiles, 
according to Eq. 3:  
             
 
 
         
  
    
    
           Eq. (3) 
where n is the sampling number, Rt and Tt are the cumulative percentage dissolved of the 
reference and the test products at each time point t. According to Moore and Flanner,21 two 
dissolution profiles are considered similar if the f2 value is between 50 and 100. 
 
2.7 Statistical analyses 
Statistical comparison among tensile properties was performed by ANOVA and Tukey-Kramer 
tests. Differences were considered significant when p-value were lower than 0.05. 
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3. Results and discussion 
 
3.1 Production and evaluation of the melatonin-loaded microparticles 
In the first part of the work, the production of solid lipid microparticles able to control the release 
of melatonin was investigated. Among the number of different lipidic carriers suitable for the 
preparation of microparticulate systems by spray congealing, tristearin and hydrogenated castor 
oil were selected due to their higher melting point. Table 1 reported the composition and the 
properties of the obtained microparticles. Considering that MP were intended to be incorporated 
in a film having a thickness lower than 100 m, an important issue was related to their size; the 
fraction of interest was then established in the range 50-75 µm. The results showed that actual 
melatonin content was quite close (> 80 %) to the theoretical one and the yield of the useful 
fraction was more influenced by the carrier rather than by the melatonin concentration (Table 1). 
The lower useful yield registered for hydrogenated castor oil was due to bigger size of 
microparticles.  
In order to detect possible drug and/or carrier solid state modification after spray congealing 
process, the microparticles were analyzed by means of DSC. In particular, the raw materials, the 
physical mixture and the corresponding melatonin-loaded and placebo microparticles were 
compared (Figure 1a and 1b). 
Figure 1a shows the data of melatonin and microparticles made of tristearin (Form. MP1-MP3). The 
DSC curve of the raw melatonin and tristearin (D) presented the characteristic endothermic peaks 
at 125°C and 79°C, respectively and their physical mixture (PM) did not present any significant 
modification of the signals. On the contrary, the placebo microparticles (MP1) showed a significant 
depression of melting peak, which shifted to 57°C. This event was attributed to the presence of 
the α form of tristearin induced by the spray congealing; α-form melting peak was followed by the 
exothermic peak of recrystallization into the stable β form, before another endothermic peak due 
to the melting of β form. This change of the original polymorphic form of tristearin due to the fast 
solidification from the melt during the spray congealing process is in agreement with previous 
data.22 However, the polymorphic modification of the carrier was not associated to any variation 
of the endothermic peak attributed to melatonin (MP3, Figure 1a). 
Figure 1b showed the results for hydrogenated castor oil systems: the DSC pattern of the carrier 
(C) evidenced a wide melting endotherm peak at 90°C with a shoulder at lower temperature. The 
corresponding thermogram of placebo (MP4) was similar to that of raw hydrogenated castor oil, 
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indicating that in this case the production process did not modify the solid state of the carrier. The 
DSC trace of melatonin loaded microparticles (MP6) was superimposable to that of the physical 
mixture and showed an endothermic peak at 90°C, due to the melting of the lipid, and a second 
endothermic peak at 120 °C, due to the melting of the melatonin.  
The enthalpies values associated to the melting of melatonin were proportional to its relative 
abundance in the formulations independently of the carrier used (data not shown) suggesting that 
the manufacturing process did not affect their original solid state of the drug. To further elucidate 
the melatonin solid state in the solid lipid microparticles, physical changes in the samples on 
heating were monitored using hot stage microscopy. This analysis confirmed the presence of 
melatonin in the naïve crystalline state (Figure 2a and 2b).  
 
Figure 1 – DSC curves of the raw melatonin and lipid carriers, their physical mixtures (PM) and the 
corresponding placebo and melatonin-loaded microparticles. a) tristearin-systems and b) 
hydrogenated castor oil-systems. 
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Figure 2 – Hot stage microscopy images of a) tristearin-based microparticles and b) hydrogenated 
castor oil microparticles (The magnification was at 10x). 
 
Finally, in vitro dissolution tests of microparticles were performed to investigate their ability to 
control the melatonin release in both simulated gastric and intestinal conditions (Figure 3). 
Melatonin completely dissolved within 10 min in both dissolution media. As expected due to the 
nature of the selected excipients, the melatonin release was not influenced by the pH of the 
dissolution media. Indeed, the melatonin showed a sustained release profiles from the 
microparticles at both gastric and intestinal pH. In particular, microparticles prepared by tristearin 
(MP2 and MP3, Table 1) released more than 50% melatonin in 60 minutes at both pH 1.2 and pH 
6.8 (Figure 3a and 3b) independently of the drug content (f2= 93 at pH 1.2 and f2 = 72 at pH 6.8). 
Similar results were obtained for hydrogenated castor macroparticles (Figure 3c and 3d): the 
melatonin release was not influenced neither by the drug content (MP5 vs MP6 at pH 1.2, f2=53; 
MP5 vs MP6 at pH= 6.8, f2=52) nor by the pH of the media (pH 1.2 vs pH 6.8 for MP5, f2=67; pH 1.2 
vs pH 6.8 for MP6, f2=90). In all cases, hydrogenated castor oil-based MP released only around 20% 
of MTL after 1 h, confirming that the lipid microparticles produced by spray congealing were useful 
systems to sustain the melatonin release.  
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Figure 3 – Melatonin release profiles of tristearin-based microparticles (MP2 and MP3) at pH1.2 (a) 
and pH 6.8 (b) and of hydrogenated castor oil-based microparticles (MP5 and MP6) at pH1.2 (c) and 
pH 6.8 (d). 
 
The results obtained in the first part of this research showed that the microparticles produced 
using hydrogenated castor oil as carrier had better performance in controlling the release of 
melatonin with respect to the tristearin ones. In addition, the MP made of tristearin started to 
melt just over 55°C, due to the formation of the polymorphic form of the carrier. This fact could be 
a disadvantage for the ODFs preparation: the drying step is carried out at 60°C, thus these 
microparticles could melt, altering their properties. Therefore, for the incorporation into the ODFs, 
the hydrogenated castor oil microparticles were selected. 
 
3.2 Film characterization 
 
3.2.1 Morphology and mechanical properties 
The melatonin loading into the placebo formulation significantly decreased the σmax (p < 0.001) 
and Y values (p = 0.0012) with respect to the placebo ODFs (F1 vs F2, F3; Table 3). In other words, 
melatonin impacted positively on the elasticity and negatively on strength of the maltodextrin-
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based ODF (F1). An opposite trend was observable for ε values (p < 0.0001), which are generally 
related to the ductility of the film. These results suggested that melatonin acts as a plasticizer for 
maltodextrin-made matrices. 
 
Table 3 – Technological performance of films loaded with microparticles and melatonin. Results 
are expressed as mean value ± standard deviation (n=5). 
Formulation 
Thickness 
(μm) 
Y 
(MPa) 
σmax 
(MPa) 
ε 
(%) 
TEB 
(MPa) 
F1 111 ± 5 1.059 ± 0.165 1.265 ± 0.077 25.30 ± 4.90 0.171 ± 0.026 
F2 110 ± 12 0.654 ± 0.123 1.091 ± 0.083 50.40 ± 7.59 0.307 ± 0.038 
F3 128 ± 2 0.393 ± 0.049 0.653 ± 0.065 68.54 ± 11.28 0.151 ± 0.017 
F6 196 ± 5 0.493 ± 0.144 0.932 ± 0.111 20.29 ± 1.40 0.136 ± 0.010 
F8 157 ± 6 0.690 ± 0.047 1.011 ± 0.100 12.89 ± 2.82 0.095 ± 0.030 
F9 235 ± 5 0.880 ± 0.098 0.569 ± 0.099 1.51 ± 0.22 0.003 ± 0.001 
 
When the MP were loaded up to 30% w/w, an increase of the film thickness (Table 3) without 
altering the inner structure of MP. These findings were also confirmed by the comparison of 
particle distribution conducted before and after the loading in the film since no significant 
differences in terms of mean value and span were observed (p > 0.05). As expected, the particle 
count resulted in agreement with the theoretical weight content of MP (Table 4). 
 
Table 4 – Particle area distribution of microparticles (MP4) loaded in ODFs (mean value ± dev.st). 
The MP4 data before drug loading was also reported as an example of the lack of modification of 
particle size distribution during the preparation of the ODF. 
Form. 
MP content 
(mg/cm2) 
Particle count 
d10 
(µm) 
d50  
(µm) 
d90  
(µm) 
Mean 
(µm) 
span 
F4 0.8 5114±112 12.48±1.90 59.41±4.53 101.76±0.00 59.92±0.37 1.51±0.08 
F5 6.0 48836±654 
16.26±0.8
8 
60.12±0.95 86.33±0.38 58.18±2.47 1.17±0.04 
F6 6.0 56967±16206 16.10±4.25 55.93±7.74 86.68±6.61 54.96±6.93 1.27±0.13 
MP4 - 16638±2017 15.36±0.05 71.33±21.39 90.77±20.41 60.45±14.84 1.06±0.03 
MP5 - 18938±1236 13.90±2.1
1 
62.53±19.69 83.91±15.97 55.54±14.71 1.14±0.14 
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Regarding the ODF tensile properties, also microparticles reduced the σmax (p < 0.01) and Y values 
(p < 0.003) in comparison to the placebo formulation (F6 vs F1; Table 3); meanwhile no significant 
changes were observed in terms of ductility and tenacity of the MPs-loaded film (F6 vs F1). On the 
contrary, the concomitant loading of melatonin and microparticles (F8, F9) significantly decreased ε 
and TEB with respect to microparticle free films (F1, F2), evidencing a synergic and negative 
influence of melatonin and microparticles on the film fragility (p < 0.0001). These results seemed 
in contrast with the plasticizer effect of melatonin observed for microparticle-free ODF. However, 
it can be explained considering that the presence of solid material, such as microparticles, may 
alter the homogeneity of the ODF matrix and result in a weaker structure of the film from a 
mechanical point of view. This effect was already described of other ODF formulations23 the 
greater the amount of powder loaded in the film the greater the film fragility. Nevertheless, even 
if F8, F9 are more fragile than other formulation, its tensile properties resulted in the range of 
agreed with those already available on the market.24 
SEM images showed that all ODFs had a regular and smooth surface (Figure 4a). The cross-section 
of the films containing microparticles (F4, F6 and F9) evidenced that the MP were homogeneously 
distributed into the films, maintaining their spherical shape. These results confirmed that the 
microparticles were successfully incorporated into the films. In addition, melatonin crystals are 
appreciable in both film surface and particle section of the F3 and F9 ODFs. 
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Figure 4 – SEM images at different magnification (a: is 250X, b: is 1000X and c: is 5000X) of ODFs: 
placebo (F1), melatonin loaded (F3), microparticle loaded (F4), microparticle-containing-melatonin 
loaded (F6), and melatonin and microparticle-containing-melatonin loaded (F9). 
 
 
3.2.2 Thermal analysis 
ODFs were also caracterized in terms of thermal properties by DSC analysis. The DSC curve of 
Form. F1 (Figure 5) showed only a wide endothermic peak between 60 and 95 °C, presumably due 
to the process of evaporation of the water contained in the film. The Form. F3, containing free 
melatonin, displayed a DSC curve with a less intense endothermic peak and slightly shifted to 
lower temperatures associated with melatoinin melting. The DSC curves of Form. F7 and F9 present 
both the endothermic peaks characteristic of the excipient (90° C) and melatonin (126° C). In 
particular, the endothermic peak of lipid carrier in Form. F9 is clearly displayed while the peak of 
the melatonin is hardly visible: only slight variation of the base line can be seen at lower 
temperatures (between 95 and 105°C) attributable to melatonin, probably due to dilution with the 
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excipients of the film. Differently, in Form. F9, the melatonin endothermick peak was more 
appreciable and shifted to higher values (between 105 and 120 °C), due to the melting of 
melatonin crystals dispersed into the film matrix. On the basis of this results it is possible to 
hypothesize that no interactions between the drug-loaded microparticles and the matrix of ODFs 
occured. 
 
 
Figure 5 – Typical DSC curves of melatonin-loaded microparticles (MP6), placebo ODF (F1), 
melatonin-loaded ODF (F3), microparticle-containing-melatonin loaded ODF (F7), melatonin and 
microparticle-containing-melatonin loaded ODF (F9). 
 
3.2.3 Melatonin release studies 
 
The last part of the research was the evaluation of melatonin release in different media from the 
ODFs. Furthermore, ODFs containing the empty microparticles (F4) were analyzed to evaluate 
possible interferences given by the components of the film.  
As expected, ODFs containing free melatonin (F2 and F3, containing 2.5% and 6% melatonin, 
respectively), showed a rapid dissolution of the drug both in Simulated Salivary Fluid (Figure 6a) 
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and Simulated Gastric Fluid (Figure 6b). The melatonin dissolved within 30 min, regardless its 
content in the ODFs. 
 
Figure 6– Dissolution profiles of F2 e F3 ODFs: (a) in simulated salivary fluid; (b) in simulated gastric 
fluid. 
 
The release studies of ODFs containing microparticles (F6 and F7) and the films containing both free 
and melatonin-loaded microparticles (F8 and F9) were performed. The Figure 7a shows the 
melatonin release pattern in Simulated Salivary Fluid over an 1 h period. The Figure 7b shows the 
drug release after exposition of the formulation to Simulated Salivary Fluid for 5 minutes to mimic 
the oral cavity, then Simulated Gastric Fluid for 1 hour to estimate the release in the stomac and, 
finally in Simulated Intestinal Fluid for 4 hours. 
As desired, the release of melatonin from the systems containing encapsulated drug (F5 and F6) 
was significantively lower respect to F2 and F3 films (compare Figure 7a with Figure 6a). The 
amount of melatonin released from F6 and F7 was lower than 20 % after 10 minutes in saliva. 
Indeed, even if the incorporation of the microparticles into the ODFs enhanced the release of 
melatoninin comparison to “free” microparticles (compare with Figure 3c and 3d), the 
microparticle was slowly released from F6 and F7, reaching the 35% and 60 % after 1 hour in SGF 
and 50% and 80%, after 5 hours, respectively (Figure 7b). The enhanced drug release from 
microparticles after incorporation in ODFs was previously observed by Brniak et al.25 and could be 
explained by the faster wetting of the microparticles while dispersed in the solubility enhancing 
agents, which formed the films (maltodextrins).  
Finally, the release behavior of films containing both free melatonin and melatonin-loaded 
microparticles at different loading (F8 and F9) was consistent with their composition: in simulated 
salivary fluid, the amount of melatonin released was intermediate respect to melatinin-loaded 
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films and microparticle-loaded ones (Figure 7a). In simulated gastric fluid most of the melatonin 
was dissolved reaching about the 70% and 90% of drug released, while in simulated intestinal fluid 
the drug release from microparticles proceeded in a controlled manner (Figure 7b). The best 
performance was thus achieved by F6 system: ODFs containing melatonin-loaded-microparticles 
allowed a sustain the drug release for at least 5 hours. 
 
 
Figure 7 – Release profiles of melatonin from F6, F7, F8 and F9 ODFs: (a) in simulated salivary fluid 
(SSF); (b) changing the composition and pH over 5 hours [5 min in SSF + 1h in simulated gastric fluid 
(SGF) + 4h in simulated intestinal fluid (SIF)]. 
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4. Conclusions 
The overall results demonstrated that ODFs made of maltodextrin can be a suitable technological 
platform for loading lipid microparticles without altering significantly both the shape and 
dimension of the microparticles and the mechanical properties of the films. Indeed, although the 
observed differences in tensile parameters among the formulations, the results agree with 
published data obtained on commercially-available ODFs. 
Thanks to the incorporation of drug-loaded hydrogenated castor oil into the ODFs, the platform 
permits to modulate the melatonin release: the amount of drug dissolved in the stomach could 
decrease the sleep onset latency, while the sustained drug release for 5 hours could increase the 
total sleep time. In addition, the innovative delivery system maintains the advantages of ODFs, 
thus is suitable for the melatonin administration to patients, such as pediatric and geriatric 
populations, with swallowing difficulties.  
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